

# Correction to “Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study”



Stephanie Perniciaro,<sup>1</sup> and Mark van der Linden \*

National Reference Center for Streptococci, Department of Medical Microbiology, University Hospital (RWTH), Aachen, Germany

The authors have noticed the data in the original [Table 4](#) of this article do not match the values reported in the text. The values in the original [Table 4](#) do not correspond to the overall vaccine effectiveness calculations; but rather, they correspond to a subset analysis of people who had only received one dose of the 23-valent pneumococcal polysaccharide vaccine.

The correct [Table 4](#) is presented below:

**The Lancet Regional Health - Europe**  
**2022;18: 100409**  
Published online xxx  
<https://doi.org/10.1016/j.lanepe.2022.100409>

DOI of original article: <http://dx.doi.org/10.1016/j.lanepe.2021.100126>

\*Corresponding author at: German National Reference Center for Streptococci, Department of Medical Microbiology, University Hospital RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany.

*E-mail address:* [mlinden@ukaachen.de](mailto:mlinden@ukaachen.de) (M. van der Linden).

© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

<sup>1</sup> Current address: Yale University School of Public Health, Department of Epidemiology of Microbial Diseases, New Haven, Connecticut, USA.

	All		vaccinated <2 years prior to IPD		vaccinated between 2 and 4 years prior to IPD		vaccinated ≥5 years prior to IPD		Age 60-69		Age 70-79		Age ≥80	
	VE (%)	95% CI (%)	VE (%)	95% CI (%)	VE (%)	95% CI (%)	VE (%)	95% CI (%)	VE (%)	95% CI (%)	VE (%)	95% CI (%)	VE (%)	95% CI (%)
PPV23 serotypes	36	10,54	-20	-130,34	56	20,76	47	17,66	71	42,86	28	-27, 58	12	-53,49
PPV23 serotypes except 3	63	49,74	49	12,71	66	37,82	69	50,81	67	33, 85	63	38, 79	60	32,77
PPV23 serotypes except 3 and 8	58	40,70	52	16,74	48	3,73	65	42,79	62	21,83	59	28, 78	51	16,72
PPV23-nonPCV13 serotypes	59	42,71	38	-7,66	67	36,84	65	42,79	78	50,92	54	21, 74	50	12,72
Serotype 3	-117	-208,-53	-179	-384,-58	-60	-201,19	-106	-229,-26	-1	-117, 56	-159	-361,-45	-176	-390,-55

**Table 4: Age- and gender-adjusted vaccine effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPV23) against invasive pneumococcal disease in people ≥60 in Germany. 95% CI shows the lower and upper bounds of the 95% confidence interval of the vaccine effectiveness estimate.**

The changes to Table 4 do not impact the final analysis or conclusions of the manuscript, but there are several places in the text where there is a discrepancy between the corrected values in the table and in the original text of the manuscript. Please use the values in this corrected table in place of the values listed in the text.